Evidence map›Paper›PMID 41787560›Full record

ArticleCancer medicine2026

CAPZA1 Suppressed the Progression of Esophageal Squamous Cell Carcinoma by Binding to hnRNP K and PTPB1 to Influence Its mRNA Stability.

Nan Kang, Yunwei Ou, Shichao Guo, Jie Chen, Dan Li, Qimin Zhan

Abstract read
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nan KangState Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0000-0003-4182-2169
Yunwei OuBeijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.
Shichao GuoState Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jie ChenLaboratory of Molecular Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Dan LiState Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0000-0002-5586-4055
Qimin ZhanState Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

National Key Research and Development Program of China 2023YFC3503200National Key Research and Development Program of China 2023YFC3503205National Natural Science Foundation of China 81490753Natural Science Foundation of Beijing Municipality 7254440the Research and Development Fund of Peking University People's Hospital RDX2024-05the Research and Development Fund of Peking University People's Hospital RDY2018-08
6 · The paper itself

Abstract

purposeEsophageal squamous cell carcinoma (ESCC) is one of the most aggressive and prevalent cancers in China, a deeper understanding at the molecular level is the cornerstone for advancing precision oncology in ESCC. This study aims to investigate the role of CAPZA1 in ESCC progression. Based on our previous whole genome sequencing (WGS) and whole exome sequencing (WES) data indicating frequent copy number loss of CAPZA1 in ESCC, as well as the presence of a specific single nucleotide polymorphism (SNP, rs373245753 T>G) in its 3'UTR via the dbSNP database (https://www.ncbi.nlm.nih.gov/snp/), we sought to determine the functional and mechanistic impact of CAPZA1 genotypes on ESCC cell behavior. MATERIALS AND

methodsWe identified the SNP rs373245753 within the 3'UTR of the CAPZA1 gene via the dbSNP database. To investigate its functional impact, we established stable ESCC cell lines overexpressing either the CAPZA1[T] or CAPZA1[G] variant and evaluated their migration and invasion capabilities using transwell assays. Subsequently, we performed subcutaneous xenograft experiments by injecting these cells into the lower limbs of mice to monitor tumor growth in vivo. Furthermore, siRNAs were used to efficiently reduce mRNA expression of CAPZA1, then xCELLigence Real-Time Cell Analyzer (RTCA)-MP system and colony formation assay were employed to detect cell proliferation ability. To elucidate the underlying molecular mechanism, we employed biotin-RNA pulldown assays coupled with mass spectrometry, along with RNA immunoprecipitation (RIP) assays, to identify RNA-binding proteins interacting with the CAPZA1 mRNA variants. Finally, we assessed the impact of these proteins on CAPZA1 mRNA stability through mRNA decay assays.

resultsAccording to the dbSNP database, we identified the SNP rs373245753 within the 3'UTR of the CAPZA1 gene. Overexpression of CAPZA1[T] significantly inhibited ESCC cell migration and invasion, while the CAPZA1[G] variant attenuated this suppression both in vivo and in vitro. Biotin-RNA pulldown combined with mass spectrometry and RIP assays showed that CAPZA1[T] mRNA binds to hnRNP K and PTBP1, enhancing its stability and tumor-suppressive function. In contrast, CAPZA1[G] mRNA preferentially bound UPF1, leading to accelerated mRNA decay and loss of tumor suppression.

conclusionCAPZA1 acts as a tumor suppressor in ESCC, with its function dependent on genotype. The CAPZA1[T] variant binds hnRNP K and PTBP1 to stabilize its mRNA and inhibit tumor aggressiveness, whereas the CAPZA1[G] allele promotes UPF1-mediated mRNA decay and diminishes this protective effect. These findings reveal a novel post-transcriptional regulatory mechanism underlying ESCC progression and highlight CAPZA1 genotype as a potential prognostic marker and therapeutic target.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaHeterogeneous-Nuclear Ribonucleoprotein KRNA Stability3' Untranslated RegionsAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMiceMice, NudePolymorphism, Single Nucleotide3' Untranslated RegionsHeterogeneous-Nuclear Ribonucleoprotein KHNRNPK protein, humanRNA-Binding Proteins3′UTResophageal squamous cell carcinoma (ESCC)mRNA stabilityRNA‐binding proteins (RBPs)single nucleotide polymorphism (SNP)suppressive functionwhole genome sequencing (WGS)

Identifiers

PMID41787560
PMCPMC12963026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.